Similar Search Results

Who is Best at Negotiating Pharmaceutical Rebates?

Abrams, Lawrence - 2016

The roll out of the new Medicare drug benefit program has renewed the debate about who is best at negotiating drug rebates with pharmaceutical manufacturers (“Pharma”). Those who favor the Federal government point to statistics showing that Medicaid gets significantly better rebates than...

Persistent link: https://www.econbiz.de/10014125027

Parallel imports and manufacturer rebates : evidence from Germany

Birg, Laura - 2019

pharmaceuticals on competition by parallel imports. First, I analyze the effect of a manufacturer rebate on competition by parallel …In this paper, I study the effect of a change in the mandatory manufacturer rebate on wholesale prices for … imports in a two-country model. An increase in the manufacturer rebate increases the market share of parallel imports. Second …

Persistent link: https://www.econbiz.de/10011949028

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25

Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …

Persistent link: https://www.econbiz.de/10012291135

External Referencing and Pharmaceutical Price Negotiation

Mariñoso, Begoña; Jelovac, Izabela; Olivella, Pau - 2011

External referencing (ER) imposes a price cap for pharmaceuticals based on prices of identical products in foreign …

Persistent link: https://www.econbiz.de/10014216337

Herd behavior in FDA committees : a structural approach

Newham, Melissa; Midjord, Rune - 2018

Many important decisions within public and private organizations are based on recommendations from expert committees and advisory boards. A notable example is the U.S. Food and Drug Administration's advisory committees, which make recommendations on new drug applications. Previously the voting...

Persistent link: https://www.econbiz.de/10011880455

Conflicts of Interest on Expert Committees : The Case of FDA Drug Advisory Committees

Cooper, James C. - 2018

Governments and firms often use committees of experts to help them make complexdecisions, but conflicts of interest could bias experts' recommendations. We focus on whetherfinancial ties to drug companies bias FDA drug advisory committee (AC) members' voting ondrug approval recommendations. We...

Persistent link: https://www.econbiz.de/10012934325

Ho, Cynthia M. - 2021

Forty percent of spiraling US drug costs are based on a mere two percent of all drugs –biologic drugs (biologics) made from living cells that are administered by injection or infusion. These costs will continue to balloon as new biologics are approved; the recently approved Alzheimer’s drug is...

Persistent link: https://www.econbiz.de/10014087594

Drug Rebates Do Not Increase Costs to Consumers

Lo Sasso, Anthony T. - 2018

the rebate system …

Persistent link: https://www.econbiz.de/10012917935

Private versus social incentives for pharmaceutical innovation

González, Paula; Macho-Stadler, Inés; … - 2015

We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a...

Persistent link: https://www.econbiz.de/10011406575

Pharmaceutical prices: the impact of the launch strategy : an analysis of German data

Böhler, Yvonne-Beatrice; Lamping, Christian; Wichardt, … - 2019

This paper reports the results from a statistical analysis of pharmaceutical price negotiations in Germany, where the … pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear … regression of 187 pharmaceuticals which were assessed from 2011 to 2017 suggests that, despite the change, the manufacturers …

Persistent link: https://www.econbiz.de/10012103333

1
2
3
4
5
6
7
8
9
10
Next
Last